Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1838
Full metadata record
DC FieldValueLanguage
dc.contributorSingh, J.en_US
dc.contributorThachil, Thanujaen_US
dc.contributorEapen, M.en_US
dc.contributorLim, A.en_US
dc.contributorSufyan, W.en_US
dc.contributorRawson, R.en_US
dc.contributorDuncan, H.en_US
dc.contributorDe Ieso, P.en_US
dc.contributorSohal, S.en_US
dc.date.accessioned2021-11-30T23:56:19Z-
dc.date.available2021-11-30T23:56:19Z-
dc.date.issued2021-
dc.identifier.govdoc01774en_US
dc.identifier.urihttp://hdl.handle.net/11054/1838-
dc.description.abstractCytokines influence the biological behaviour of prostate cancer (PC) and may influence patient outcome and serve as useful prognostic biomarkers. The aim of the present study was to evaluate cytokine expression levels in prostatic needle biopsy specimens and the association with clinicopathological characteristics of patients with PC. A total of 18 patients with PC who underwent transrectal ultrasound (TRUS) guided prostate biopsy were included in the clinical study. These patients were naïve to radiotherapy (RT) or androgen deprivation therapy prior to TRUS biopsy and clinical follow up data was collected. Cytokine expression levels were analysed by using immunohistochemistry and Spearman's correlation test was used to determine the correlation between cytokine expression and clinicopathological characteristics. Expression levels of pro‑inflammatory TNF‑α and IL‑6 decreased as Gleason score (GS) increased; however, a statistically significant difference was not detected. A statically significant correlation was observed between needle biopsy specimen and pre‑RT plasma sample expression levels of pro‑inflammatory TNF‑α and IL‑6 (P=0.01 and P=0.05, respectively) and anti‑inflammatory TGF‑β1 (P=0.05). However, further studies are needed to confirm these results using a larger sample size to confirm the prognostic value of pro‑inflammatory TNF‑α and IL‑6 and anti‑inflammatory TGF‑β1 in patients with PC.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2021-11-10T01:11:43Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2021-11-30T23:56:19Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2021-11-30T23:56:19Z (GMT). No. of bitstreams: 0 Previous issue date: 2021en
dc.titleImmunohistochemical investigation of cytokine expression levels as biomarkers in transrectal ultrasound‑guided needle biopsy specimens of prostate adenocarcinoma.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleMolecular and Clinical Oncologyen_US
dc.bibliographicCitation.volume15en_US
dc.bibliographicCitation.issue3en_US
dc.bibliographicCitation.stpage191en_US
dc.subject.healththesaurusCYTOKINE EXPRESSIONen_US
dc.subject.healththesaurusPROSTATE CANCERen_US
dc.subject.healththesaurusIMMUNOHISTOCHEMICAL STAININGen_US
dc.subject.healththesaurusPROSTATIC NEEDLE BIOPSY SPECIMENen_US
dc.identifier.doihttps://doi.org/10.3892/mco.2021.2353en_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.